Enovis earnings date
Enovis (C520) Q3 2026 Earnings Report
DE:C520 Q3 2026 EPS Results
- Actual EPS
- EUR 0.79
- Consensus EPS
- EUR 0.69
- Beat/Miss
- Beat by +EUR 0.10
- One Year Ago EPS
- EUR 0.67
DE:C520 Q3 2026 Revenue Results
- Actual Revenue
- EUR 500.25M
- Expected Revenue
- EUR 498.82M
- Beat/Miss
- Beat by +EUR 1.43M
- YoY Revenue Growth
- +1.79%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- Before Open
- Conference Call
- Thursday, November 5, 2026
Enovis's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly constructive. The company delivered 5% organic growth, expanded adjusted margins, increased EPS and free cash flow, raised EBITDA and EPS guidance, and reported momentum from Nebula, ARVIS, Manifuse, and the planned Essential Robotics acquisition. These positives outweighed challenges from market volatility, international pressure, pricing and inflationary costs, softer U.S. hips and knees, and currency headwinds.
For the full year, Innovus narrowed revenue guidance to $2.32 billion to $2.35 billion, expects organic growth to be approximately 5%, increased adjusted EBITDA guidance to $428 million to $438 million, raised adjusted earnings per share guidance to $3.58 to $3.79, and continues to expect free cash flow conversion of greater than 25% in 2026; for Q4, it expects modest acceleration in both segments, driven by Arvest and Shoulder, continued Nebula conversions, and new products in P&R, with an incremental $4 million investment in enabling technology R&D talent and a $1 million negative impact from currency, while its outlook assumes the procedural environment seen in the third quarter holds through year-end with typical Q4 seasonality. For next year, management sees a step up to at least 50% free cash flow conversion and a $100 million of cash generation, expects foot and ankle to grow high single digit plus over time, and expects to bring the knee robot to market within 2 years and shoulder to follow soon thereafter.
- Solid Third-Quarter Organic GrowthThird-quarter sales were $559 million, up 2% on a reported basis and up 5% organically. Recon grew 6% organically and P&R grew 3% organically.
- Recon Growth Across Key MarketsU.S. Recon grew 5% organically, with extremities up 5% and hips and knees up 3%. International Recon grew 8% organically, led by double-digit shoulder growth.
- Continued Product Momentum in ExtremitiesARG continues to be described as a strong future growth opportunity. The company is expanding ARVIS into shoulder and completed its first ARVIS shoulder cases in Europe last month.
- Nebula Driving Hip and Knee Share GainsMore than 80% of new Nebula instrumentation sets went to competitive users during the quarter. Nebula is now the company's top-selling stem, and management said it remains in the early stages of a multiyear product cycle.
- Progress in Ambulatory Surgery CentersA little over 25% of primary knee procedures and about 20% or slightly more of hip procedures are going through ASCs. Shoulder procedures through ASCs are in the high teens, and management identified ASC expansion as a continued strategic focus.
- Essential Robotics Acquisition ProgressThe company completed the works council consultation for Essential Robotics and expects the transaction to close by the end of the year. Integration planning is well underway, with the company investing to secure the talent and technology needed to accelerate development.
- Robotics Development Timelines MaintainedManagement said the timelines for Essential Robotics remain unchanged, with the knee robot expected to reach the market within 2 years and the shoulder robot to follow soon thereafter.
- Positive Customer and Employee Response to Essential RoboticsManagement reported a great response from customers in both knee and shoulder, as well as enthusiasm from representatives. The company views the ability to offer an ecosystem spanning planning, navigation, assistance, and robotics across hospitals and ASCs as a significant opportunity.
- P&R Growth Supported by New ProductsP&R grew 3% organically, including 5% organic growth in the U.S. Global bracing grew 3%, driven by business mix and new products in spine, core knees, and lower-extremity bracing.
- Recovery Science and Manifuse MomentumRecovery Science was driven by double-digit growth in regenerative products as the company accelerated the launch of Manifuse and benefited from key competitive conversions.
- Improved Gross and EBITDA MarginsAdjusted gross margin was 60.9%, up 60 basis points, driven by mix and operational productivity. Adjusted EBITDA margin was 18.5%, up 120 basis points year over year.
- Strong Adjusted EPS GrowthAdjusted earnings per share was $0.88, up 17% versus the prior year.
- Meaningful Free Cash Flow ImprovementThird-quarter free cash flow was $35 million, bringing year-to-date free cash flow to $37 million, up $50 million versus the prior year. Management maintained its 2026 target of greater than 25% free cash flow conversion.
- Leverage Below Yearly Goal and Share Repurchase AuthorizationThe company exited the quarter with net leverage of 2.9x, below its stated goal for the year. The board authorized a new $200 million share repurchase program, with management planning to operate within a 2.5x to 3.5x leverage range.
- Raised Full-Year Profit GuidanceFull-year revenue guidance was narrowed to $2.32 billion to $2.35 billion, with organic growth expected to be approximately 5%. Adjusted EBITDA guidance increased to $428 million to $438 million, and adjusted EPS guidance increased to $3.58 to $3.79.
- Expected Fourth-Quarter AccelerationManagement expects modest acceleration in both segments in the fourth quarter, driven by ARVIS and shoulder, continued Nebula conversions, and new P&R products. An extra selling day is expected to contribute about 150 basis points or slightly more to top-line growth.
- Lima Integration Tracking to PlanThe third year of Lima integration is tracking to the company's stated plans. Management said this will be the last big meaningful year of Lima integration investments, and Lima synergies continue to contribute to mix and gross-margin improvement.
- Shoulder Portfolio Maintaining Competitive PositionThe company said it is the global No. 3 shoulder player and No. 2 internationally, and is approaching the No. 2 position globally. Management reported strong uptake and interest in the ARVIS platform and continued share gains.
- P&R Portfolio and MotionMD DifferentiationMore than 50% of the P&R portfolio is growing at mid-single-digit or greater rates. MotionMD has a 99% customer satisfaction rating, with management reporting a significant and growing customer base and demonstrated ability to reduce clinic inventory and improve claims processing speed.
- Foot and Ankle Portfolio OutlookManagement said underlying foot and ankle performance through the first nine months was very positive, with additional innovations planned later this year and into next year. The company expects the business to grow into the high-single-digit range over time.
- Continued Investment in Recon and Enabling TechnologyThe company expects an incremental $4 million investment in enabling-technology R&D talent in the fourth quarter to support Essential Robotics. Management also said CapEx as a percentage of sales is expected to decline over the next couple of years while CapEx continues to grow because of recon investments.
DE:C520 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | 0.92- | 0.85 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | 0.690.79 | 0.67 | 17.33% (+0.12) | |
| Aug 06, 2026 | 2026 (Q2) | 0.760.81 | 0.71 | 13.92% (+0.10) | |
| May 07, 2026 | 2026 (Q1) | 0.730.80 | 0.73 | 9.88% (+0.07) | |
| Feb 26, 2026 | 2025 (Q4) | 0.750.85 | 0.88 | -3.06% (-0.03) | |
| Nov 06, 2025 | 2025 (Q3) | 0.580.67 | 0.65 | 2.74% (+0.02) | |
| Aug 07, 2025 | 2025 (Q2) | 0.640.71 | 0.56 | 27.42% (+0.15) | |
| May 08, 2025 | 2025 (Q1) | 0.670.73 | 0.45 | 62.00% (+0.28) | |
| Feb 26, 2025 | 2024 (Q4) | 0.820.88 | 0.71 | 24.05% (+0.17) | |
| Nov 06, 2024 | 2024 (Q3) | 0.550.65 | 0.5 | 30.36% (+0.15) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
